| 2025 | 2024 | 2023 | 2022 | 2021 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12,8 M € | +10.6% | 11,6 M € | +23.1% | 9,4 M € | +10.1% | 8,6 M € | +46.5% | 5,8 M € | -19.3% | 7,2 M € | -6.1% | 7,7 M € | -4.6% | 8,1 M € | +3.0% | 7,8 M € | -10.1% | 8,7 M € | +11.8% | 7,8 M € | -7.3% | 8,4 M € | +10.2% | 7,6 M € | -0.1% | 7,6 M € | -18.0% | 9,3 M € | +207.2% | 3,0 M € | +3.4% | 2,9 M € | |
| EBITDA | 920,6 k € | +2097.0% | 41,9 k € | -96.5% | 1,2 M € | +127.5% | 519,3 k € | +64.2% | 316,2 k € | -53.5% | 679,9 k € | +204.9% | -648,4 k € | -129.2% | 2,2 M € | +96.7% | 1,1 M € | +17.5% | 961,9 k € | +0.3% | 959,3 k € | -36.6% | 1,5 M € | +74.4% | 867,8 k € | +363.5% | -329,3 k € | -112.3% | 2,7 M € | +3601.2% | -76,3 k € | +47.5% | -145,4 k € | |
| Operating profit | 729,4 k € | +31.2% | 556,0 k € | +24.4% | 446,8 k € | +124.7% | 198,8 k € | -15.1% | 234,2 k € | +74.7% | 134,1 k € | -71.9% | 477,1 k € | -3.2% | 493,0 k € | +178.8% | 176,8 k € | -61.6% | 460,0 k € | +22.0% | 376,9 k € | -62.3% | 1,0 M € | +244.2% | 290,7 k € | +129.1% | -1,0 M € | -158.2% | 1,7 M € | +297.2% | -871,5 k € | +35.3% | -1,3 M € | |
| Profit/loss | 577,4 k € | +30.0% | 444,0 k € | +38.6% | 320,4 k € | +225.9% | 98,3 k € | -25.3% | 131,6 k € | +321.8% | -59,3 k € | -106.4% | 924,4 k € | +33.7% | 691,3 k € | +68.0% | 411,3 k € | -55.6% | 926,0 k € | +51.8% | 609,9 k € | -51.4% | 1,3 M € | +129.1% | 548,4 k € | +187.1% | -629,8 k € | -131.2% | 2,0 M € | +562.7% | -436,1 k € | +22.8% | -564,7 k € | |
| Equity | 7,4 M € | +8.5% | 6,8 M € | +7.0% | 6,4 M € | +5.3% | 6,0 M € | +1.6% | 5,9 M € | +2.2% | 5,8 M € | -52.3% | 12,2 M € | -33.3% | 18,3 M € | +3.9% | 17,6 M € | +2.1% | 17,2 M € | +6.5% | 16,2 M € | +3.8% | 15,6 M € | +8.7% | 14,3 M € | +3.9% | 13,8 M € | -4.5% | 14,4 M € | +38.9% | 10,4 M € | -6.9% | 11,2 M € | |
| Total assets | 10,7 M € | +10.7% | 9,7 M € | +8.5% | 8,9 M € | -1.2% | 9,0 M € | +26.3% | 7,1 M € | +0.8% | 7,1 M € | -64.8% | 20,1 M € | +2.6% | 19,6 M € | +2.9% | 19,0 M € | +4.1% | 18,3 M € | +2.5% | 17,8 M € | +4.6% | 17,0 M € | +6.9% | 15,9 M € | +7.3% | 14,9 M € | -18.0% | 18,1 M € | +8.6% | 16,7 M € | +4.9% | 15,9 M € | |
| Cash | 474,6 k € | +29.7% | 365,8 k € | +52.4% | 240,1 k € | -50.3% | 482,6 k € | +21.2% | 398,1 k € | -46.3% | 741,8 k € | +50.6% | 492,6 k € | +27.3% | 387,0 k € | +39.2% | 278,0 k € | -7.1% | 299,2 k € | +51.0% | 198,1 k € | -31.4% | 288,6 k € | -21.1% | 366,0 k € | +157.0% | 142,4 k € | -47.6% | 272,0 k € | +245.6% | 78,7 k € | -52.7% | 166,4 k € | |
| Debts | 3,3 M € | +15.9% | 2,9 M € | +12.2% | 2,5 M € | -14.3% | 3,0 M € | +148.8% | 1,2 M € | -3.9% | 1,2 M € | -84.2% | 7,9 M € | +501.9% | 1,3 M € | -9.1% | 1,4 M € | +37.2% | 1,1 M € | -36.1% | 1,6 M € | +13.6% | 1,4 M € | -9.4% | 1,6 M € | +50.9% | 1,1 M € | -71.2% | 3,7 M € | -41.6% | 6,3 M € | +33.2% | 4,7 M € | |
| Staff | 68,9 | 66,2 | 64,4 | 64,9 | 64,1 | 67 | 74,8 | 78,6 | 76,5 | 70,2 | 67,3 | 66,8 | 64,7 | 70,5 | 60,1 | 36,8 | 35 | |||||||||||||||||
Public limited company · Liège · incorporated on 16/02/1989 · 68,9 ETP
Public limited company profitable and well capitalised. Cash position rising (+29.7%).
Solid counterparty for a standard engagement.
IMMUNODIAGNOSTIC SYSTEMS is a Public limited company incorporated in 1989. Its main activity is: Manufacture of other chemical products n.e.c.. Its registered office is in Liège. It employs on average 68,9 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette